![]() |
市場調查報告書
商品編碼
2149245
細胞增殖市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。Cell Expansion Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
全球細胞增殖市場預計到2025年將達到221.4億美元,並從2026年的248.2億美元成長至2034年的540.4億美元,預測期內複合年成長率(CAGR)為10.22%。截至2025年,北美將佔全球細胞增殖市場51.81%的佔有率,成為推動其成長的主要動力。細胞和基因治療、再生醫學、組織工程、藥物研發和生物製藥製造等領域的進步是推動該市場擴張的主要因素。
細胞增殖是指在實驗室條件下對活細胞進行可控制的生長和增殖,用於治療、研發和工業應用。對先進細胞療法的投資增加以及自動化細胞培養技術的開發正在推動市場成長。 2025年6月,Celltrio獲得500萬美元投資,用於推進細胞培養和細胞/基因治療應用的自動化解決方案。賽默飛世爾科技、丹納赫公司和賽多利斯公司等企業正透過產品開發和策略舉措來強化其業務組合。
細胞增殖市場的關鍵點
市場規模及預測:預計2025年市場規模為221.4億美元,2026年達248.2億美元,2034年達540.4億美元。 2026年至2034年,市場預計將以10.22%的複合年成長率成長。
市佔率:預計到 2025 年,北美將佔 51.81% 的市佔率。自動化和封閉式系統預計將以 13.63% 的複合年成長率成長,而免疫細胞預計將以 13.71% 的複合年成長率成長。
主要區域趨勢:預計北美地區到 2025 年將達到 114.7 億美元,歐洲地區到 2026 年將達到 64 億美元,亞太地區到 2025 年將達到 35.2 億美元。
市場動態
市場促進因素:慢性病盛行率上升以及細胞和基因療法的廣泛應用。
癌症、心血管疾病和遺傳性疾病的日益普及推動了對創新細胞療法的需求。細胞增殖是產生足夠數量細胞用於治療的關鍵。因此,對細胞和基因療法以及再生醫學的投資增加正在支撐市場成長。
市場限制:GMP級細胞增殖高成本。
符合GMP規範的細胞增殖高成本,仍是主要的阻礙因素。專用設施、先進設備、品管和監管要求都會增加生產成本。這些費用可能會限制小規模生物技術公司和研究機構獲得治療藥物的機會。
市場機會:異體細胞療法的興起
異體細胞療法的進步為可擴展的細胞生產創造了機會。與自體療法不同,異體療法使用供體細胞,從而支持「現成」療法的開發。對異體生產平台投資的增加預計將進一步刺激對細胞增殖技術的需求。
市場挑戰:熟練工人短缺
細胞增殖需要專門的實驗室知識和技術專長。訓練有素的專業人員短缺會使先進系統的操作以及利用細胞進行的研究和生產活動難以進行。
細胞增殖市場趨勢
將人工智慧整合到設備中
將人工智慧 (AI) 整合到細胞增殖設備中正成為一股重要趨勢。 AI 系統能夠改善細胞處理、成像、監測、自動化和流程最佳化。數位技術的日益普及正在推動更精準、更有效率的細胞研究和生產。
細胞增殖市場細分分析
依產品類型
市場細分分為設備和機械、耗材以及軟體和服務。預計到2025年,耗材將成為市場成長的主要驅動力,這主要得益於對培養基、血清、試劑、生長因子、微載體和一次性生物製程材料的持續需求。設備和機械細分市場預計將以8.82%的複合年成長率成長。
透過技術
市場涵蓋貼壁細胞增殖技術、懸浮細胞增殖技術、自動化密封系統等。 2025年,貼壁細胞增殖技術將佔41.9%的市場佔有率,主要得益於幹細胞研究和再生醫學領域的應用。自動化密封系統預計將以13.63%的複合年成長率成長。
細胞類型
該市場涵蓋幹細胞、免疫細胞和分化細胞。預計到2025年,幹細胞將成為市場成長的主要驅動力,佔36.8%的市場佔有率,這主要得益於幹細胞療法的進步。免疫細胞細分市場預計將以13.71%的複合年成長率成長。
用途別
市場細分包括細胞療法和再生醫學、生物製藥生產、藥物發現與開發等領域。預計到2025年,生物製藥生產將佔41.9%的市場。細胞療法和再生醫學領域預計將以12.58%的複合年成長率成長。
最終用戶
預計到2025年,製藥和生技公司將成為市場的主要驅動力,佔45.2%的市場。藥物發現和研究以及細胞療法開發的投資增加,正在支撐市場需求。學術和研究機構預計將以7.51%的複合年成長率成長。
細胞增生市場區域展望
北美洲
北美將繼續保持區域市場的領先地位,到 2025 年將達到 114.7 億美元。在美國,由於先進的研究基礎設施、對細胞療法的投資以及主要市場參與企業的存在,到 2025 年美國市場將達到 109.1 億美元。
歐洲
預計到 2026 年,歐洲的年複合成長率將達到 10.00%,市場規模將達到 64 億美元。 2025 年,英國、德國和法國的市場規模分別為 12.5 億美元、11.6 億美元和 9.1 億美元。
亞太地區
預計到2025年,亞太地區市場規模將達35.2億美元,成為全球第三大區域市場。印度和中國預計到2025年市場規模將分別達到6.2億美元和6.4億美元。由於再生醫學和先進細胞療法的日益普及,日本仍然是一個重要的市場。
拉丁美洲
預計到 2025 年,拉丁美洲的市場規模將達到 8.9 億美元。這一成長是由參與企業的擴張以及人們對細胞和基因療法自動化生產日益成長的興趣所推動的。
中東和非洲
預計中東和非洲市場將保持溫和成長。海灣合作理事會(GCC)市場在醫療和生物技術領域的投資增加下,預計到2025年將達到2.6億美元。
The global cell expansion market size was valued at USD 22.14 billion in 2025 and is projected to grow from USD 24.82 billion in 2026 to USD 54.04 billion by 2034, exhibiting a CAGR of 10.22% during the forecast period. North America dominated the global cell expansion market with a 51.81% market share in 2025. The market is expanding due to the increasing development of cell and gene therapies, regenerative medicine, tissue engineering, drug discovery, and biopharmaceutical manufacturing.
Cell expansion involves the controlled growth and multiplication of living cells under laboratory conditions for therapeutic, research, and industrial applications. Increasing investments in advanced cell-based therapies and the development of automated cell culture technologies are supporting market growth. In June 2025, Celltrio secured USD 5.0 million in investment to advance automation solutions for cell culturing and cell and gene therapy applications. Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius AG, and other companies are strengthening their portfolios through product development and strategic initiatives.
CELL EXPANSION MARKET KEY TAKEAWAYS
Market Size & Forecast: The market was valued at USD 22.14 billion in 2025, is projected to reach USD 24.82 billion in 2026, and is expected to reach USD 54.04 billion by 2034. The market is expected to grow at a 10.22% CAGR from 2026-2034.
Market Share: North America accounted for 51.81% in 2025. Automated and closed systems are expected to grow at a 13.63% CAGR, while immune cells are projected to grow at a 13.71% CAGR.
Key Regional Highlights: North America reached USD 11.47 billion in 2025, while Europe is projected to reach USD 6.40 billion in 2026. Asia Pacific reached USD 3.52 billion in 2025.
MARKET DYNAMICS
MARKET DRIVERS: Rising Prevalence of Chronic Diseases and Growing Adoption of Cell & Gene Therapies
The rising prevalence of cancer, cardiovascular disorders, and genetic diseases is increasing demand for innovative cell-based treatments. Cell expansion is essential for producing sufficient quantities of cells for therapeutic applications. Growing investments in cell and gene therapies and regenerative medicine are therefore supporting market expansion.
MARKET RESTRAINTS: High Cost of GMP-Grade Cell Expansion
The high cost of GMP-grade cell expansion remains a major restraint. Specialized facilities, advanced equipment, quality controls, and regulatory requirements increase production costs. These expenses can limit accessibility for smaller biotechnology companies and research organizations.
MARKET OPPORTUNITIES: Emergence of Allogenic Cell Therapies
The growing development of allogenic cell therapies is creating opportunities for scalable cell manufacturing. Unlike autologous approaches, allogenic therapies use donor cells and can support the development of off-the-shelf treatments. Increasing investment in allogenic manufacturing platforms is expected to create further demand for cell expansion technologies.
MARKET CHALLENGES: Limited Availability of Skilled Personnel
Cell expansion requires specialized laboratory knowledge and technical expertise. A shortage of trained professionals can create difficulties in operating advanced systems and scaling cell-based research and manufacturing activities.
CELL EXPANSION MARKET TRENDS
Integration of AI in Instruments
The integration of artificial intelligence into cell expansion instruments is emerging as an important trend. AI-enabled systems can improve cell handling, imaging, monitoring, automation, and process optimization. Increasing adoption of digital technologies is supporting more accurate and efficient cell research and manufacturing.
CELL EXPANSION MARKET SEGMENTATION ANALYSIS
By Product Type
The market is segmented into instruments and equipment, consumables, and software and services. Consumables dominated the market in 2025, supported by recurring demand for media, sera, reagents, growth factors, microcarriers, and single-use bioprocessing materials. The instruments and equipment segment is expected to grow at a 8.82% CAGR.
By Technology
The market includes adherent cell expansion technologies, suspension cell expansion technologies, automated and closed systems, and others. Adherent cell expansion technologies held a 41.9% share in 2025, supported by applications in stem cell research and regenerative medicine. Automated and closed systems are expected to grow at a 13.63% CAGR.
By Cell Type
The market includes stem cells, immune cells, differentiated cells, and others. Stem cells dominated with a 36.8% share in 2025, driven by increasing development of stem cell-based therapies. The immune cells segment is expected to grow at a 13.71% CAGR.
By Application
The market is segmented into cell therapy and regenerative medicine, biopharmaceutical production, drug discovery and development, and others. Biopharmaceutical production held a 41.9% share in 2025. The cell therapy and regenerative medicine segment is projected to grow at a 12.58% CAGR.
By End User
Pharmaceutical and biotechnology companies dominated the market with a 45.2% share in 2025. Increasing drug discovery, research investments, and cell-based therapy development are supporting demand. Academic and research institutes are expected to grow at a 7.51% CAGR.
CELL EXPANSION MARKET REGIONAL OUTLOOK
NORTH AMERICA
North America remained the leading regional market, reaching USD 11.47 billion in 2025. The U.S. market reached USD 10.91 billion in 2025, supported by advanced research infrastructure, cell therapy investments, and the presence of major market participants.
EUROPE
Europe is projected to record a 10.00% CAGR and reach USD 6.40 billion in 2026. The U.K., Germany, and France recorded USD 1.25 billion, USD 1.16 billion, and USD 0.91 billion, respectively, in 2025.
ASIA PACIFIC
Asia Pacific reached USD 3.52 billion in 2025, making it the third-largest regional market. India and China recorded USD 0.62 billion and USD 0.64 billion, respectively, in 2025. Japan remains an important market due to increasing adoption of regenerative medicine and advanced cell-based therapies.
LATIN AMERICA
Latin America recorded USD 0.89 billion in 2025. Increasing expansion by market participants and growing interest in automated cell and gene therapy manufacturing are supporting regional development.
MIDDLE EAST & AFRICA
The Middle East & Africa market is expected to experience moderate growth. The GCC market reached USD 0.26 billion in 2025, supported by increasing healthcare and biotechnology investments.
COMPETITIVE LANDSCAPE
Key Industry Players: Expansion of Product Offerings and Research Activities
The global cell expansion market is fragmented, with numerous companies operating across different product and technology categories. Major companies include Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius AG, Merck KGaA, Lonza Group, Corning Incorporated, BD, Terumo Corporation, Miltenyi Biotec, and Eppendorf SE.
KEY INDUSTRY DEVELOPMENTS
September 2025: Sartorius AG expanded its manufacturing facility in Illkirch, France, supporting the production of transfection reagents for cell and gene therapies.
August 2025: Danaher Corporation's Cytiva collaborated with Culture Biosciences to integrate cloud-connected bioreactor technology for digital bioprocessing.
March 2025: Cytiva expanded the Xcellerex X-platform portfolio with 500-L and 2,000-L bioreactors for advanced therapeutic manufacturing.
October 2024: Terumo Corporation expanded its presence in Latin America to support automated manufacturing solutions for cell and gene therapy companies.
October 2023: Terumo Corporation and BioCentriq collaborated on automated cell and gene therapy platforms for CAR-T cell development.
REPORT COVERAGE
The global cell expansion market report covers market size and forecast for 2025, 2026, and 2034, along with segmentation by product type, technology, cell type, application, end user, and geography. The report includes market dynamics, trends, opportunities, challenges, technological advancements, product launches, strategic collaborations, and competitive developments.
CONCLUSION
The global cell expansion market is projected to increase from USD 22.14 billion in 2025 to USD 24.82 billion in 2026 and reach USD 54.04 billion by 2034. Rising adoption of cell and gene therapies, increasing demand for regenerative medicine, expansion of biopharmaceutical manufacturing, and development of automated and closed cell expansion systems are supporting market growth. North America remains the leading regional market, while Europe and Asia Pacific are expanding through investments in cell-based research, advanced therapies, and biomanufacturing technologies.
Segmentation By Product Type, Technology, Cell Type, Application, End User, and Region
By Product Type
By Technology
By Cell Type
By Application
By End User
By Geography